Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (691-700 of 1,037) with videos related to

Pageof 104
Sort By:
Research Square|May 25, 2026
Intranasal CRISPR- lipid nanoparticles targeting MAPK9 reduce neuroinflammation after traumatic brain injuryGoknur Kara, Yaqoob Ali, Jessica López-Espinosa, et al.
Pesticide Biochemistry and Physiology|June 11, 2025
Characterization of N-arylamide insecticides to control populations of the green peach aphid, Myzus persicaeFlinn M O'Hara, Sarah E Mccomic, Zhijun Liu, et al.
British Journal of Haematology|August 19, 2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemiaFarrukh T Awan, Peter Hillmen, Andrzej Hellmann, et al.
Journal of Molecular and Cellular Cardiology|August 3, 2021
IL4Rα signaling promotes neonatal cardiac regeneration and cardiomyocyte cell cycle activitySamantha J Paddock, Samantha K Swift, Victor Alencar-Almeida, et al.
Cancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Gregory A Wiseman, et al.
The Oncologist|July 9, 2017
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic LeukemiaWilliam Donnellan, Jesus G Berdeja, Diana Shipley, et al.
Cytokine|March 17, 2009
Echinacea tennesseensis ethanol tinctures harbor cytokine- and proliferation-enhancing capacitiesDavid S Senchina, Dustin A McCann, Gina N Flinn, et al.
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Vascular and Endovascular Surgery|August 21, 2007
Intraoperative coil embolization reduces transplant nephrectomy transfusion requirementDavid G Neschis, Rao Gutta, Hosam S Al-Qudah, et al.
Pageof 104

Showing results (691-700 of 1,037) with videos related to

Sort By:
Pageof 104
Research Square|May 25, 2026
Intranasal CRISPR- lipid nanoparticles targeting MAPK9 reduce neuroinflammation after traumatic brain injuryGoknur Kara, Yaqoob Ali, Jessica López-Espinosa, et al.
Pesticide Biochemistry and Physiology|June 11, 2025
Characterization of N-arylamide insecticides to control populations of the green peach aphid, Myzus persicaeFlinn M O'Hara, Sarah E Mccomic, Zhijun Liu, et al.
British Journal of Haematology|August 19, 2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemiaFarrukh T Awan, Peter Hillmen, Andrzej Hellmann, et al.
Journal of Molecular and Cellular Cardiology|August 3, 2021
IL4Rα signaling promotes neonatal cardiac regeneration and cardiomyocyte cell cycle activitySamantha J Paddock, Samantha K Swift, Victor Alencar-Almeida, et al.
Cancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Gregory A Wiseman, et al.
The Oncologist|July 9, 2017
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic LeukemiaWilliam Donnellan, Jesus G Berdeja, Diana Shipley, et al.
Cytokine|March 17, 2009
Echinacea tennesseensis ethanol tinctures harbor cytokine- and proliferation-enhancing capacitiesDavid S Senchina, Dustin A McCann, Gina N Flinn, et al.
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Vascular and Endovascular Surgery|August 21, 2007
Intraoperative coil embolization reduces transplant nephrectomy transfusion requirementDavid G Neschis, Rao Gutta, Hosam S Al-Qudah, et al.
Pageof 104